An open-label, proof-of-mechanism trial evaluating a neuroactive steroid GABA modulator in tinnitus.

ABSTRACT: Imbalances of excitatory and inhibitory signaling within the central auditory pathways are hypothesized to underlie tinnitus pathophysiology. Neuroactive steroids, such as allopregnanolone, are positive allosteric modulators of GABA_A receptors that regulate neuronal signaling in part through their binding affinity for and inhibitory action at extrasynaptic GABA_A receptors. This pilot, single-arm, proof-of-mechanism trial investigated whether brexanolone, an intravenous formulation of allopregnanolone, may improve tinnitus symptomatology. Adults between 18 and 65 years of age with bilateral, chronic, moderate tinnitus were recruited in this single-arm, open-label study. Ten participants received a 6-h infusion of brexanolone (30 min at 30 mcg/kg/h, 30 min at 60 mcg/kg/

SUBMITTER: Watson LS 

PROVIDER: S-EPMC12668930 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature